Thus, the phase III FLEX study involving patients with advanced NSCLC showed a strong correlation between high tumour EGFR overexpression and the efficacy of adding cetuximab to platinum based first-line chemotherapy [12]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.